Difluprednate Ophthalmic Emulsion 0.05% is a generic therapeutic equivalent version of Novartis Pharmaceutical’s Durezo.
The drug is indicated in the US for the treatment of inflammation and pain resulting from ocular surgery, and treatment of endogenous anterior uveitis.
Cipla gets FDA approval for generic version of Novartis’ Durezo. Image courtesy of Clker-Free-Vector-Images from Pixabay.
As per IQVIA (IMS Health), Durezol had sales of nearly $106 million in the US for the 12-month period ending June 2021.
Cipla Limited has expanded its presence in the ophthalmology market through a multi-regional licensing agreement with Formosa Pharmaceuticals, granting it exclusive rights to commercialize APP13007, an advanced ophthalmic suspension. This strategic partnership covers 11 markets, including India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, and Colombia,…
In a significant development for the global pharmaceutical industry, Lupin Limited (Lupin) has announced its latest achievement: receiving approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution, 0.075%. This approval marks a pivotal step for Lupin, granting…
Global pharmaceutical titan, Lupin Limited, has officially declared its success in securing the esteemed approval from the United States Food and Drug Administration (FDA). This sanction is specific to Lupin's Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution at a concentration of 0.09%. With this, Lupin is now green-lighted…
In "Pharma Industry News"
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
